ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Serum Lipidomic Analysis of T2DM Patients: A Potential Biomarker Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Maternal and cord blood lipidomics as predictors of autism spectrum disorders: A systematic review.Metabolism open · 2025Review
- Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse Model.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Comprehensive analysis of serum lipidomics is important for the treatment and prevention of type 2 diabetes (T2DM). The purpose of this study was to provide a profile of lipid changes in the serum of T2DM patients and identify potential lipid biomarkers. Patients and Methods: In this study, we collected clinical physiological parameters and determined the serum lipid profiles of 30 T2DM patients and 30 matched healthy volunteers using the UPLC-MS method. Results: Based on the above test, 1162 lipid metabolites were detected, of which 267 were significantly altered in the T2DM group (FDR < 0.05), which belonged to the five main lipid classes. Eleven lipids were identified as potential lipid biomarkers with the specific screening criteria (variable importance in the projection (VIP) >1.0; P < 0.05; log Conclusion: The results of this study revealed important changes in lipids in T2DM patients, expanded the knowledge of lipid levels and T2DM progression, and provided important metabolic information for the therapy and diagnosis of T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.